Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma

More documents

Recommendations

Info

2. Bilateral abnormalities in neuropathic pain Thermal hypesthesias were observed also in most of the patients for CDT, WDT and TSL. For MDT there was predominantly a sensory loss observed indicating a mechanical hypesthesia. It was possible to detect hyperesthesia for VDT for one patient, but for the large majority VDT responses indicated hypesthesia. In 25% (n=20) of the patients a sensory gain for PHS was detected at the affected side. DMA was present in 26% of the patients, in 6% of very mild intensity, however, 20% of patients showed a clinical relevant increased response for DMA indicating a dynamic allodynia. 3.3.3. Sensory changes at the patient’s contralateral side Sensory abnormalities at the contralateral side ranged from 1.2% (n=1) for CPT to 29.6% (n=24) for PPT. With the exception of CPT, 95% Confidence Intervals confirmed that the prevalence differed significantly from zero (p
2. Bilateral abnormalities in neuropathic pain Fig 2-3: Quantitative Sensory Testing (QST) z-score abnormalities in % at the affected (left) and contralateral side (right) in 81 neuropathic pain patients. QST parameter are ordered as sensory parameters: Cold Detection Threshold (CDT), Warm Detection Threshold (WDT), Thermal Sensory Limen (TSL), Mechanical Detection Threshold (MDT), Vibration Disappearance Threshold (VDT), Paradoxical Heat Sensation (PHS), Dynamic Mechanical Allodynia (DMA) and nociceptive parameters: Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), Pressure Pain Threshold (PPT), Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity (MPS) and Wind Up Ratio (WUR). Z-scores with positive sensory signs (gain of sensory function) plotted rightwards and negative sensory signs (loss of sensory function) plotted leftwards. Absence of DMA is normal and therefore no negative sign possible.
Page 2: Quantitative Sensory Testing (QST)
Page 5 and 6: Promotores: Prof. dr. M.M.R.F. Stru
Page 7 and 8: Paranimfen Marten Harbers Aribert B
Page 9 and 10: Contents 3.3.4. Sensory changes at
Page 11: 0 Contents Chapter 5 Do patients wi
Page 14: Chapter 1 General introduction
Page 17 and 18: 1. General introduction stimuli. C-
Page 19 and 20: 1. General introduction Patients re
Page 21 and 22: 1. General introduction 0 drugs (NS
Page 23 and 24: 1. General introduction Table 1-2:
Page 26 and 27: Chapter 2 Bilateral sensory abnorma
Page 28 and 29: 2. Bilateral abnormalities in neuro
Page 46: 2. Bilateral abnormalities in neuro
Page 49 and 50: 3. Somatosensory function and neuro
Page 51 and 52: 0 3. Somatosensory function and neu
Page 67 and 68: 4. QST and neuropathic pain mechani
Page 81 and 82: 5. QST in patients with tendinopath
Page 89 and 90:
5. QST in patients with tendinopath
Page 91 and 92:
5. QST in patients with tendinopath
Page 94 and 95:
Chapter 6 General discussion and Su
Page 96 and 97:
6. General discussion and Summary s
Page 98 and 99:
6. General discussion and Summary s
Page 100 and 101:
6. General discussion and Summary T
Page 102 and 103:
6. General discussion and Summary Q
Page 104 and 105:
6. General discussion and Summary S
Page 106 and 107:
References Abate M, Silbernagel KG,
Page 108 and 109:
de la Llave-Rincon AI, Fernandez-de
Page 110 and 111:
Kehlet H, Jensen TS, Woolf CJ. 2006
Page 112 and 113:
Robinson JM, Cook JL, Purdam C, Vis
Page 114 and 115:
Visentini PJ, Khan KM, Cook JL, Kis
Page 116 and 117:
Nederlandse samenvatting Met de ont
Page 118 and 119:
Acknowledgement To produce a work s
show all

Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma

Create successful ePaper yourself

Delete template?

Save as template?